Title: David Louis Shelton: Innovator in Antibody-Drug Conjugates
Introduction
David Louis Shelton is a notable inventor based in the United States. He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. His work focuses on enhancing drug delivery systems to improve treatment outcomes.
Latest Patents
David Shelton holds two notable patents. The first patent, titled "Antibody-Drug Conjugates With High Drug Loading," presents a method for creating transglutaminase-mediated antibody-drug conjugates with a high antibody-drug ratio (DAR). This invention includes glutamine-containing tags and amine donor agents, achieving a DAR of at least about 5. The second patent, "Treatment Of Chronic Prostatitis," relates to the use of an anti-NGF antibody for treating or preventing pain and lower urinary tract symptoms associated with chronic prostatitis and chronic pelvic pain syndrome.
Career Highlights
Throughout his career, David has worked with prominent companies in the pharmaceutical industry. He has been associated with Pfizer Corporation and Rinat Neuroscience Corporation, where he contributed to innovative research and development projects.
Collaborations
David has collaborated with several professionals in his field, including Ian William Mills and Arnon Rosenthal. These collaborations have furthered his research and development efforts in biotechnology.
Conclusion
David Louis Shelton is a distinguished inventor whose work in antibody-drug conjugates has the potential to transform treatment methodologies in medicine. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.